

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |  |   |
|---|--|--|---|
| (51) International Patent Classification <sup>6</sup> :<br><br>A01N 43/40   |  | A1   | (11) International Publication Number: <b>WO 99/30562</b><br><br>(43) International Publication Date: 24 June 1999 (24.06.99) |
| (21) International Application Number: PCT/US98/26646   |  | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). |   |
| (22) International Filing Date: 15 December 1998 (15.12.98)   |  |  |   |
| (30) Priority Data:<br>08/991,913 16 December 1997 (16.12.97) US  |  |  |   |
| (71) Applicant: CORNELL RESEARCH FOUNDATION, INC. [US/US]; Suite 105, 20 Thornwood Drive, Ithaca, NY 14850 (US).  |  |  |   |
| (72) Inventors: HANAUSKE-ABEL, Hartmut, M.; 1055 River Road #510S, Edgewater, NJ 07020 (US). MCCAFFREY, Timothy, A.; 450 East 63rd #3K, New York, NY 10021 (US). GRADY, Robert, W.; 11 Alpine Drive, Kinnelon, NJ 07405 (US). |  | Published<br><i>With international search report.</i>  |   |
| (74) Agents: GOLDMAN, Michael, L. et al.; Nixon, Hargrave, Devans & Doyle LLP, Clinton Square, P.O. Box 1051, Rochester, NY 14603 (US).   |  |  |   |


## (54) Title: METHOD FOR TREATING FIBROPROLIFERATIVE DISORDERS BY INHIBITORS OF PROTEIN HYDROXYLATION

## (57) Abstract



The present invention relates to a method of treating conditions mediated by collagen formation together with cell proliferation by administering to a patient or living system an effective amount of a compound of Formulae (I) or (II) and derivatives thereof: R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

Deferiprone blocks endothelial cell tube formation.  
*An in vitro model of angiogenesis.*

Untreated human endothelial cells form capillary-like tubes (ARROW) when placed on Matrigel for 4 to 24 hours.



Deferiprone treated endothelial cells attach and spread but do not form capillary-like tubes on Matrigel.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |   |    |                          |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania                  | ES | Spain                                 | LS | Lesotho                                   | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                               | LT | Lithuania                                 | SK | Slovakia                 |
| AT | Austria                  | FR | France                                | LU | Luxembourg                                | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                 | LV | Latvia                                    | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                        | MC | Monaco                                    | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                               | MD | Republic of Moldova                       | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                 | MG | Madagascar                                | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                | ML | Mali                                      | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                               | MN | Mongolia                                  | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                               | MR | Mauritania                                | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                | MW | Malawi                                    | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                               | MX | Mexico                                    | US | United States of America |
| CA | Canada                   | IT | Italy                                 | NE | Niger                                     | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                 | NL | Netherlands                               | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                 | NO | Norway                                    | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                            | NZ | New Zealand                               | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's Republic of Korea | PL | Poland                                    |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                     | PT | Portugal                                  |    |                          |
| CN | China                    | KZ | Kazakhstan                            | RO | Romania                                   |    |                          |
| CU | Cuba                     | LC | Saint Lucia                           | RU | Russian Federation                        |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                         | SD | Sudan                                     |    |                          |
| DE | Germany                  | LK | Sri Lanka                             | SE | Sweden                                    |    |                          |
| DK | Denmark                  | LR | Liberia                               | SG | Singapore                                 |    |                          |
| EE | Estonia                  |    |                                       |    |   |    |                          |

**METHOD FOR TREATING FIBROPROLIFERATIVE DISORDERS BY INHIBITORS OF PROTEIN HYDROXYLATION**

5

**Field of the Invention**

This invention relates to the treatment of conditions mediated by collagen formation together with cell proliferation.

10

**Background of the Invention**

15

The local formation of a new connective tissue matrix by resident and immigrant cells which on site may also multiply to varying degrees, is part of the physiological, beneficial healing response of all human tissues. In many common, clinically diverse diseases, this fibroproliferative response becomes itself detrimental, however, and produces an abnormal accumulation of fibrocellular scar tissue that further compromises the normal function of the affected tissue and in time, becomes the main cause for morbidity and mortality in these conditions. Examples include, but are not limited to:

20

- All forms of liver fibrosis and cirrhosis, which over the past decades consistently ranks among the ten most common causes of death in the United States. Among the causes that can lead to this condition are: acute and chronic infections, particularly with viruses causing hepatitis; ingestion of toxins, such as alcohol; and autoimmune and genetic abnormalities.

25

- All forms of lung fibrosis, from coal miners' Black Lung Disease to the treatment-induced varieties occurring in cancer patients and premature babies. The fibrocellular scar tissue severely compromises the biophysical parameters of pulmonary function, typically reducing diffusion capacity, vital capacity, and compliance, and progresses relentlessly to respiratory failure and death.

30

- All forms of vascular fibrosis, the process underlying atherosclerosis and diabetic complications. While vascular fibrosis exhibits many varied forms and consequences, typical consequences include angina pectoris, myocardial infarction, stroke, and kidney failure.
- All forms of detrimental scarring triggered by interventional therapies, from restenosis of blood vessels and hollow organs to complications

35

after eye surgery. Restenosis of the coronaries, for instance, occurs in about 40% of all balloon angioplasties and atherectomies performed in the United States each year to treat coronary atherosclerosis, leading directly to morbidity and mortality in some 200,000 patients annually.

5

In the formation and maintenance of this fibrocellular scar tissue, one of the pivotal biochemical events centers on the hydroxylation of the following proteins by specialized intracellular enzymes. These are :

10

- The hydroxylation of the collagens by the enzyme prolyl 4-hydroxylase, forming trans 4-hydroxyproline ("Hyp") residues. The proteins of the collagen family are uniquely distinct from other proteins as only they contain Hyp residues. The collagens constitute the major extracellular building blocks of the fibrocellular scar tissue, and cannot be deposited if Hyp-deficient.

15

- The hydroxylation of the ribosomal protein eIF-5A by the enzyme deoxyhypusine hydroxylase, forming hypusine ("Hps") residues. eIF-5A is required for the biosynthesis of proteins that control cell multiplication, which cannot occur if cells are Hps-deficient.

20

- The hydroxylation of the chaperone LTBP by the enzyme aspartyl/asparaginyl hydroxylase, forming hydroxyaspartate ("Has") and hydroxyasparagine ("Han") residues. LTBP mediates the correct folding of bioactive transforming growth factor  $\beta$  ("TGF- $\beta$ "), the key hormone controlling formation of fibrocellular scar tissue. Has/Han-deficient LTBP presumably fails in this chaperone function, resulting in the formation of misfolded, biologically inactive TGF- $\beta$ .

25

Inhibitors of these protein hydroxylases block the biochemical events that are required for the formation of excessive fibrocellular scar tissue, and therefore have anti-fibroproliferative properties of clinical importance.

30

A number of pharmaceutical compounds have been developed to treat various forms of fibrosis or fibroproliferative conditions.

U.S. Patent No. 4,248,892 to Kanamara, et al. relates to a method for treating fibrosis by administering to a mammal 3,4-dihydroxybenzoic acid and 3,4-dihydroxyphenylacetic acid and their physiologically acceptable salts.

35

U.S. Patent No. 4,260,599 to Okazaki discloses the antifibrotic substance P1894B, having specified physical and chemical properties, which is

produced by culturing a microorganism belonging to the genus *Streptomyces* and capable of producing P1894B in culture.

U.S. Patent No. 4,912,111 to Sank discloses a method for accelerating healing of wounds by oral or topical administration of minoxidil.

5 U.S. Patent No. 4,904,675 to Winter-Mihaly discloses pyridine-3-carboxylic acids and esters containing a substituted or unsubstituted 5-tetrazolyl group in the 6-position of the pyridine ring, or tautomers or salts thereof; these compounds are useful as antifibrotic agents as a result of their inhibition of collagen proline hydroxylase.

10 U.S. Patent No. 4,937,266 to Tomikawa et al., discloses a method of inhibiting hepatic fibrosis by administering pantethine. It is noted that such administration inhibited an increased prolyl hydroxylase activity in the liver with hepatic fibrosis.

15 U.S. Patent No. 4,997,854 to Kagan et al., discloses a method for inhibiting enzymatic activity of lysyl oxidase *in situ* using 1,2-diamine compounds; these compounds can also be used as anti-fibrotic agents.

U.S. Patent Nos. 5,182,297 and 5,252,608 to Palfreyman disclose a method of treating fibrotic conditions with 3,3-dihalo-2-propenylamine compounds and their salts, which are inhibitors of lysyl oxidase.

20 U.S. Patent No. 5,260,323 to Baader et al., discloses 2,4- or 2,5-disubstituted pyridine N-oxide compounds; these compounds inhibit proline hydroxylase and lysine hydroxylase. Also disclosed is a method of treating a subject in need of a fibrosuppressive or immunosuppressive effect.

25 U.S. Patent No. 4,514,420 to Imada et al., discloses a method for treating a mammal suffering from fibrosis with an effective amount of a 2,3-dialkyl-5,6-dimethoxy-p-benzoquinone compound.

U.S. Patent No. 4,569,943 to Okazaki et al., discloses particular 5-hydroxy-1,4-naphthoquinone compounds and antifibrotic preparations containing them.

30 U.S. Patent No. 5,204,338 to Baader et al., discloses a pharmaceutical composition comprising particular oxallyl amino acid compounds and their physiologically active salts. These compounds are said to inhibit prolyl hydroxylase and lysine hydroxylase. Also disclosed are methods for influencing metabolism of collagen with effective amounts of these compounds.

35 U.S. Patent No. 5,252,735 to Morris discloses particular 2-amino-6-phenyl-4H-pyran-4-one compounds, which are useful as antiatherosclerotic agents

and inhibitors of cell proliferation and/or platelet aggregation; preferred compounds contain an N-morpholino substituent in the 2- position of the pyranone ring.

U.S. Patent No. 5,132,119 to Lee discloses methods of reducing scar tissue and fibromatosis by administering a calcium channel blocker into a wound. The calcium channel blocker is chosen from nifedipine, hydroxyridine, verapamil, cobalt chloride, and biologically acceptable cobalt salts.

U.S. Patent No. 4,797,471 to Teetz et al. discloses use of peptide derivatives as fibrosuppressive agents.


U.S. Patent No. 5,037,839 to Bickel et al. discusses the use of pyridine-2,4- and -2,5-dicarboxylic acid amides to influence metabolism of collagen.

Despite the existence of all of these substances for treating various forms of fibrosis, the need continues for development of other more effective materials.

15

### Summary of the Invention

The present invention relates to a method of treating conditions mediated by collagen formation together with cell proliferation by administering to a patient or living system an effective amount of a compound of Formulae (I) or (II) and derivatives thereof:



25

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

While not wishing to be bound by theory, since the compounds of the Formulae (I) and (II), according to this invention, inhibit the enzymatically catalyzed hydroxylations of proteins, they are apt to prevent the maturation of such proteins which do not become biologically functional until in their hydroxylated forms. These hydroxylase-dependent proteins are, for instance, the collagens, the ribosomal initiation factor eIF-5A, and LTBP, the chaperone for synthesis of bioactive TGF- $\beta$ . If their hydroxylation is suppressed by inhibition of the enzymes which catalyze this reaction, i.e. prolyl 4-hydroxylase, deoxyhypusyl hydroxylase, and aspartyl/asparaginyl hydroxylase, respectively, these proteins are rendered unable to function. As the functions of these hydroxylase-dependent proteins converge in the clinical disease group of fibrotic and fibroproliferative conditions, the protein hydroxylase inhibitors of Formulae (I) and (II) are suitable instruments to control and treat such conditions pharmacologically.

15

#### Brief Description of the Drawings

20

Figure 1 shows the inhibition of purified human prolyl 4-hydroxylase, relative to uninhibited enzyme activity, by several representative hydroxypyridone compounds. The effect on the enzyme was determined in a cell-free system by measuring the oxidative decarboxylation of its cofactor 2-oxoglutarate via release of radiolabeled carbon dioxide in a standard reaction mixture also containing ascorbate, ferrous sulfate, and unhydroxylated peptide substrate.

25

Figure 2 shows the chromatographic profile of metabolically labeled hypusine/deoxyhypusine obtained after incubation of purified rat deoxyhypusyl hydroxylase with unhydroxylated eIF-5A in the absence (open squares) and presence of mimetic A (closed squares). Mimetic A is only weakly inhibitory itself, but useful as a carrier for appropriately positioned moieties of Formulae (I) or (II).

30

Figures 3a and 3b shows the inhibition of cellular human deoxyhypusyl hydroxylase, relative to uninhibited enzyme activity, by several representative hydroxypyridone compounds. In Figure 3a, the effect on the human enzyme was determined by measuring in proliferating cultured B-lymphocytes the covalent incorporation of tritiated spermidine-derived label into cellular protein, after standard hydrolysis, chromatographic separation of amino acids, and expression of the results relative to uninhibited controls. In Figure 3b, a standard chromatographic elution profile is shown as obtained from cultured human smooth muscle cells ("SMC"), grown out of coronary atherosclerotic lesions and metabolically labeled in

the absence and presence of L-mimosine. In its absence, the tritiated spermidine-derived label occurs in a peak corresponding to Hps, whereas in its presence the label is shifted to the unhydroxylated precursor of Hps, i.e., deoxyhypusine.

5       Figure 4a shows, as percent of uninhibited controls, the suppressive effect of L-mimosine on prolyl 4-hydroxylation in cultured human smooth muscle cells ("SMC") obtained from coronary restenotic lesions. Those SMC, immunocytochemically identified by reactivity to contractile  $\alpha$ -actin as shown in Figure 4b, were pretreated with inhibitor for 30 minutes prior to routine metabolic labeling with tritiated proline (" $^3$ H-Pro") for 24 hours, followed by standard hydrolysis and separation of amino acids from both supernatant and cells. The degree of inhibition of scar collagen formation was determined by measuring formation of tritiated hydroxyproline (" $^3$ H-Hyp").

10

15       Figure 5 shows, as percent of uninhibited controls, the suppressive effect of six hydroxypyridone compounds on prolyl 4-hydroxylation in a human lung fibroblast line ("MRC-5"). Those cells were pretreated with inhibitor for 30 minutes prior to routine metabolic labeling with tritiated proline ("Pro") for 24 hours, followed by standard hydrolysis and separation of amino acids from both supernatant and cells for determination of proline conversion into hydroxyproline ("Hyp"). To demonstrate 20 the selective inhibition of collagen secretion by these compounds, the extracellular counts representing Hyp within collagen proteins and the extracellular counts representing Pro within non-collagen proteins were determined by standard methods, then normalized to 1 million cells and expressed relative to uninhibited controls.

25       Figures 6a and 6b show the selectively suppressive effect of the representative hydroxypyridone L-mimosine on only the secretion of human type I and III collagens, but not on release of plasminogen activator inhibitor-1 ("PAI-1") activity, as produced by cultured human SMC obtained from restenotic coronary lesions. Type III collagen biosynthesis (Figure 6a) was assessed by a commercial radioimmunoassay using a monoclonal antibody to the N-terminal propeptide of 30 type III procollagen. Plasminogen activator inhibitor-1 ("PAI-1") activity was measured by a standard enzymatic method. Type I collagen biosynthesis (Figure 6b) was assessed by routine Western blot using a monoclonal antibody to the C-terminal propeptide of type I procollagen.

35       Figure 7 shows the non-toxic reversibility of the inhibitory effect of hydroxypyridones on cell proliferation, as exemplified by the effect of L-mimosine on the proliferation of SMC derived from human coronary atherosclerotic lesions. The

effect of the structural hydroxypyridone analog kojic acid is shown for comparison. Serum-stimulated DNA synthesis in SMC was determined by a 4-hour pulse of  $^3\text{H}$ -thymidine given 20 hours after treatment with L-mimosine and kojic acid (filled symbols). Identically treated, but unlabeled cells cultured in parallel, at that time 5 point were washed and returned to fresh culture media without inhibitor for an additional 20 hours prior to otherwise identical labeling with  $^3\text{H}$ -thymidine (open symbols). Data is expressed as  $^3\text{H}$ -thymidine incorporated per cell to compensate for the reduced cell number in the wake of inhibitor treatment.

Figure 8 depicts the anti-fibroproliferative mode of action of 10 compounds of Formulae (I) or (II) mediated by inhibition of protein hydroxylases, as schematically shown here for prolyl 4-hydroxylase and deoxyhypusyl hydroxylase. The diagram emphasizes the similarity in active site organization between these two 15 particular enzymes with regard to i) their respective peptide substrate, which in each case displays a -Gly-x-y-Gly motif (glycine residues highlighted in gray); ii) the orientation of this peptide substrate in relation to the active site metal (M); and iii) the organization of the active site; where the metal is located within a pocket inside of the protein proper, symbolized by the hatched area, and in this manner shielded from the outside and accessible only to inhibitors of a certain geometry. The active site metal (M), is thought to generate and orient a reactive oxygen atom species (O) for 20 stereospecific attack on the prolyl C4 and the deoxyhypusyl C9 atoms, in this way mediating hydroxylation (arrows). It is claimed that compounds of Formulae (I) or (II) are able to block its role in catalysis. Inhibition of prolyl 4-hydroxylase directly suppresses the hydroxyproline-dependent formation and secretion of triple helical 25 collagens, whereas inhibition of deoxyhypusyl hydroxylase compromises cell proliferation.

Figure 9 shows the effect of deferiprone on endothelial cells proliferation. Human umbilical vein endothelial cells ("HUVEC") were treated with the specified 30 concentrations of deferiprone (X-axis) for 24 hours prior to evaluating tritiated thymidine ( $^3\text{H}$ -Tdr) incorporation into DNA for 4 hours. The results are expressed per well and the bars at each point reflect the standard error of the mean (S.E.M., n=3). Decreasing  $^3\text{H}$ -Tdr incorporation would reflect reduced endothelial cells proliferation.

Figures 10 A-B show that deferiprone blocks endothelial cell tube formation. HUVEC form tubes when plated on Matrigel and this is a commonly used as an *in* 35 *vitro* model of capillary formation. In the Figure 10A, it is shown that untreated HUVEC form capillary-like tubes (ARROW) when placed on Matrigel for 24 hours.


As shown in Figure 10B, deferiprone-treated endothelial cells attach and spread, but do not form capillary-like tubes on Matrigel.

Detailed Description of the Invention

5

The present invention relates to a method of treating conditions mediated by collagen formation together with cell proliferation by administering to a patient or living system an effective amount of a compound of Formulae (I) or (II) and derivatives thereof:

10



15

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

20

The alkyl, alkenyl, alkoxy, aryl, aralkyl, and cycloalkyl groups represented by R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> can be substituted or unsubstituted. Examples of unsubstituted alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, pentyl, hexyl, and the like. Unsubstituted alkenyl groups can be 2-propenyl, 2-but enyl, 3-butenyl, 2-methyl-2-butenyl, and the like. Unsubstituted alkoxy groups can be methoxy, ethoxy, propoxy, isopropoxy, and the like. Unsubstituted aryl groups can be phenyl or naphthyl. Aralkyl groups can be, for example, benzyl and phenylethyl. Cycloalkyl groups can be cyclopentyl, cyclohexyl, 4-methyl cyclohexyl, and the like. For substituted alkyl, alkenyl, alkoxy, aryl, aralkyl, and cycloalkyl groups, substituents can include, for example, halo, alkoxy, amino, hydroxy, carboxy,

25

carboalkoxy, and carbamyl. Aryl and aralkyl groups can, in addition, contain alkyl substituents.

The post-translational hydroxylations of the hydroxylation-dependent proteins occur within highly specific motifs of their primary structure. For example, these motifs are -G-x-m\*-G- for prolyl 4-hydroxylase, -G-m\*-x-G- for deoxyhypusyl hydroxylase, and -C-x-m\*-x(4)-[F/Y]-x-C-x-C- for aspartyl/asparaginyl hydroxylase, with m\* indicating the position of the substrate residue to be modified by hydroxylation, i.e. prolyl, deoxyhypusyl, or aspartyl/asparaginyl, respectively, G being glycine, x indicating the presence of any residue, C being cysteine, F being phenylalanine, and Y being tyrosine. It is generally accepted that all protein hydroxylases, when hydroxylating artificial substrates of the correct motif alone, show low or very low affinity for such substrates. This is attributed to the fact that these short motifs do not present themselves to the enzymes' active site in the conformation known to be optimal for hydroxylation, a conformation easily assumed, however, within the structure of a larger peptide or the native substrate protein. To overcome this lack of affinity, suitable peptide motifs or their corresponding peptidomimetics, termed 'carriers', can be equipped with a reactive moiety, termed 'warhead', that is precisely positioned to interact with the active site metal ion common to all these protein hydroxylases (see Figure 8). Directed to the enzyme of interest by the appropriate carrier, the warhead interacts with the active site metal, locking the carrier to the enzyme and in this manner, enhances the inhibitory capacity of the carrier which otherwise may be either non- or only weakly inhibitory. This concept is termed "warhead strategy" and is applicable to the rational design of all motif-guided protein hydroxylase inhibitors. As to Formulae (I) and (II), such a warhead strategy is effected where R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and/or R<sub>4</sub> is a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms. The warhead strategy requires that the warheads, which may themselves be inhibitory for the protein hydroxylases, must fit their respective active sites and must be reasonably stable under biological conditions, e.g., not susceptible to redox cycling. Consequently, warheads can consist of moieties of Formulae (I) or (II), for instance, properly positioned on a suitable carrier for optimal anti-fibroproliferative effect.

Table I contains representative forms of the hydroxypyridone compounds of Formula (I) of the present invention:

- 10 -

Table I

| Trivial name           | R <sub>1</sub>  | R <sub>2</sub>                   | R <sub>3</sub>   | R <sub>4</sub>   |
|------------------------|---|----------------------------------|------------------|------------------|
| L-mimosine             | -CH <sub>2</sub> CH(COOH)NH <sub>2</sub>  | H                                | H                | H                |
| HK1, CP20, L1,<br>DMHP | -CH <sub>3</sub>  | -CH <sub>3</sub>                 | H                | H                |
| HK2, CP94              | -CH <sub>2</sub> CH <sub>3</sub>  | -CH <sub>2</sub> CH <sub>3</sub> | H                | H                |
| CP93                   | -CH <sub>3</sub>  | -CH <sub>2</sub> CH <sub>3</sub> | H                | H                |
| CP96                   | -(CH <sub>2</sub> ) <sub>2</sub> OCH <sub>3</sub>                                   | -CH <sub>2</sub> CH <sub>3</sub> | H                | H                |
| HK26, CP21             | -CH <sub>2</sub> CH <sub>3</sub>  | -CH <sub>3</sub>                 | H                | H                |
| HK27, CP22             | -(CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>                                    | -CH <sub>3</sub>                 | H                | H                |
| HK16                   | -CH <sub>2</sub> CH=CH <sub>2</sub>   | -CH <sub>3</sub>                 | H                | H                |
| CP23                   | -CH(CH <sub>3</sub> ) <sub>2</sub>  | -CH <sub>3</sub>                 | H                | H                |
| CP40                   | -(CH <sub>2</sub> ) <sub>2</sub> OH   | -CH <sub>3</sub>                 | H                | H                |
| CP41                   | -(CH <sub>2</sub> ) <sub>3</sub> OH   | -CH <sub>3</sub>                 | H                | H                |
| CP42                   | -(CH <sub>2</sub> ) <sub>4</sub> OH   | -CH <sub>3</sub>                 | H                | H                |
| CP43                   | -(CH <sub>2</sub> ) <sub>5</sub> OH   | -CH <sub>3</sub>                 | H                | H                |
| CP44                   | -(CH <sub>2</sub> ) <sub>2</sub> NH <sub>2</sub>                                    | -CH <sub>3</sub>                 | H                | H                |
| CP51                   | -(CH <sub>2</sub> ) <sub>2</sub> OCH <sub>3</sub>                                   | -CH <sub>3</sub>                 | H                | H                |
| HK15                   | -CH <sub>2</sub> OCH <sub>2</sub> CH <sub>3</sub>                                   | -CH <sub>3</sub>                 | H                | H                |
| CP54                   | -(CH <sub>2</sub> ) <sub>3</sub> OCH <sub>2</sub> CH <sub>3</sub>                   | -CH <sub>3</sub>                 | H                | H                |
| CP52                   | -(CH <sub>2</sub> )OCH <sub>2</sub> CH <sub>3</sub>                                 | -CH <sub>3</sub>                 | H                | H                |
|                        | -CH <sub>3</sub>  | H                                | -CH <sub>3</sub> | H                |
|                        | -CH <sub>3</sub>  | H                                | H                | -CH <sub>3</sub> |
|                        | -CH <sub>2</sub> CH(COO <sub>2</sub> C <sub>2</sub> H <sub>5</sub> )NH <sub>2</sub> | H                                | H                | H                |

5

Table II contains representative forms of the hydroxypyridone compounds of Formula (II) of the present invention:

Table II

| R <sub>1</sub>                                    | R <sub>2</sub>                   | R <sub>3</sub>   | R <sub>4</sub>   |
|---|----------------------------------|------------------|------------------|
| -CH <sub>3</sub>                                  | -CH <sub>3</sub>                 | H                | H                |
| -CH <sub>2</sub> CH <sub>3</sub>                  | -CH <sub>2</sub> CH <sub>3</sub> | H                | H                |
| -CH <sub>3</sub>                                  | -CH <sub>2</sub> CH <sub>3</sub> | H                | H                |
| -(CH <sub>2</sub> ) <sub>2</sub> OCH <sub>3</sub> | -CH <sub>2</sub> CH <sub>3</sub> | H                | H                |
| -CH <sub>2</sub> CH <sub>3</sub>                  | -CH <sub>3</sub>                 | H                | H                |
| -(CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>  | -CH <sub>3</sub>                 | H                | H                |
| -CH <sub>3</sub>                                  | H                                | -CH <sub>3</sub> | H                |
| -CH <sub>3</sub>                                  | H                                | H                | -CH <sub>3</sub> |

10


### Compounds of Formula (I)

Compounds of Formula (I) are synthesized by one of several general procedures.

15

Method A

This method is adapted from Kontoghiorghe and Sheppard (Inorg. Chim. Acta 136:L11-L12 (1987)), which is hereby incorporated by reference. In brief, a 3-hydroxy-4-pyrone is refluxed for approximately 6 hours with three equivalents of a primary amine dissolved in an appropriate solvent. The reaction mixture is decolorized with charcoal, filtered, and the filtrate evaporated to give a dark residue. The residue is recrystallized from one to three times from an appropriate solvent to yield a solid product with a narrow melting point and an NMR spectrum consistent with the structure anticipated.



15

In particular, 3-hydroxy-2-methyl-4-pyrone (10 g) was refluxed for 6.5 hours with three equivalents of aqueous methylamine (40%) in 200 ml of water. The reaction mixture was allowed to cool after which decolorizing charcoal was added to the solution, and the mixture was stirred for 0.5 hours. After filtration, the solvent was evaporated under reduced pressure, and the solid residue recrystallized three times from water to yield 1,2-dimethyl-3-hydroxypyrid-4-one (HK-1, L1, CP20, DMHP) as fine white needles.


20

In a slight modification of this procedure, N-carboxymethyl-3-hydroxy-2-methylpyrid-4-one is prepared as described by Zhang et al., Can. J. Chem. 70:763-770 (1992) which is hereby incorporated by reference. One equivalent of 3-hydroxy-2-methyl-4-pyrone and two equivalents of glycine are dissolved in hot distilled water; the pH is adjusted to approximately 9 with 8 N sodium hydroxide, and the reaction mixture is heated under reflux for 20 hours. After cooling and decolorizing with charcoal, approximately half of the solvent is removed under vacuum and 6 N hydrochloric acid is added to reduce the pH to approximately 3. A yellow solid precipitates which yields the product as off-white crystals after two recrystallizations from water (mp 258-260°C).

30

Method B

This method is adapted from GB Patent No. 2,118,176A to Hider et al., which is hereby incorporated by reference. In brief, a 3-hydroxy-4-pyrone is converted to the corresponding 3-benzyloxy-4-pyrone via reaction with benzyl chloride. A methanolic solution of the pyrone is added to an aqueous solution of sodium hydroxide after which benzyl chloride is added and the reaction mixture refluxed for approximately 6 hours. The solvent is evaporated under reduced pressure, water is added, and then the product is extracted into an appropriate organic solvent. After washing, the extract is dried over anhydrous magnesium sulfate and the solvent evaporated to yield the crude 3-benzyloxy derivative which is used in the next step without further purification. To a solution of the 3-benzyloxy compound in an appropriate solvent is added a slight excess of primary amine. The reaction mixture is stirred at room temperature for approximately 6 days after which it is acidified to pH 2 with concentrated hydrochloric acid and evaporated to dryness. The residue is washed with water and extracted into an appropriate organic solvent which is then dried over magnesium sulfate and evaporated to dryness. To the residue is added hydrobromic acid. This reaction mixture is heated on a steam bath for 30 minutes and then recrystallized from water to yield the N-substituted 3-hydroxypyrid-4-one. The product melts sharply and has an NMR spectrum consistent with the desired product.



5                   In particular, 2-ethyl-3-hydroxy-4-pyrone (24.7 g) in 225 ml of methanol is added to 25 ml of water containing 7.5 g of sodium hydroxide. To this solution is added benzyl chloride (25.5 g) and the mixture is then refluxed for 6 hours. Upon cooling, the solvent is removed under reduced pressure. The residue is treated with 50 ml of water and then extracted three times with 25-ml aliquots of dichloromethane. The combined extracts are washed twice with 5% (w/v) sodium hydroxide, then twice with 25 ml of water and dried over magnesium sulfate.


10                  Evaporation of the solvent yields crude 3-benzyloxy-2-ethyl-4-pyrone. This crude pyrone (24.4 g) and 1.56 g of methylamine hydrochloride are then dissolved in 300 ml of aqueous ethanol (100 ml) containing 2 g of sodium hydroxide. The solution is stirred at room temperature for 6 days, acidified to pH 2 with concentrated hydrochloric acid, and then evaporated to dryness. The residue is washed with water and extracted twice into chloroform (50 ml). The combined extracts are dried over anhydrous magnesium sulfate and evaporated to dryness yielding 3-benzyloxy-2-ethyl-1-methylpyrid-4-one. To 2 g of this pyrid-4-one is added concentrated hydrobromic acid (10 ml). The reaction mixture is heated on a steam bath for 30

15                  minutes and the product recrystallized from water to yield 2-ethyl-3-hydroxy-1-methylpyrid-4-one.

20

**Method C**

This method is adapted from that of Bartulin et al., *J. Heterocyclic Chem.* 29:1017-1019 (1992), which is hereby incorporated by reference. A 3-benzyloxy-4-pyrone, prepared as in Method B, is added to an ethanolic solution of aqueous ammonia. The reaction mixture is stirred for approximately 3 days, concentrated under reduced pressure, triturated with acetone, and the solid recrystallized from ethanol to yield the corresponding 3-benzyloxypyrid-4-one. To a solution of this pyrid-4-one in aqueous ethanol containing one equivalent of sodium hydroxide is added an equivalent of n-alkyl bromide. The reaction mixture was heated under reflux for 24 hours after which it was cooled, concentrated under reduced pressure, and extracted with an appropriate solvent. After washing, the organic phase with water, it is dried over magnesium sulfate. The product is obtained upon concentration of the solution under reduced pressure. Crude 1-alkyl-3-benzyloxypyrid-4-one in acetic acid containing 40% hydrobromic acid is then heated on a steam bath for 30 minutes. The 1-alkyl-3-hydroxypyrid-4-one precipitates and is subsequently recrystallized from benzene in good yield with a narrow melting point and appropriate NMR spectrum.




In particular, 3-benzoyloxy-2-methyl-4-pyrone was prepared as described in Method B. A solution containing 15.3 g of the pyrone, 160 ml of aqueous ammonia (25%) and 80 ml of ethanol is stirred at room temperature for 3 days. The solvent is removed under reduced pressure and some acetone added. The solid which precipitates is collected by filtration and recrystallized from ethanol to yield (80%) 3-benzoyloxy-2-methylpyrid-4-one with a melting point of 162-163°C. A solution containing 0.125 moles of the pyrid-4-one, 0.125 moles of n-hexyl bromide, 0.125 moles of sodium hydroxide, 25 ml of water, and 200 ml of ethanol is heated under reflux for 24 hours. After removal of the solvent under vacuum, the residue is extracted with ethyl ether. The etherial solution is washed with water yielding a precipitate which is crystallized from benzene after drying to give 3-benzoyloxy-1-hexyl-2-methylpyrid-4-one (95%, mp 46°C). A solution of this compound in 80 ml of acetic acid containing 40% hydrobromic acid is then heated on a steam bath for 30 minutes. The product is filtered off and crystallized from benzene to yield 1-hexyl-3-hydroxy-2-methylpyrid-4-one in 70% yield.

### Compounds of Formula (II)

Compounds of Formula (II) are synthesized by the general procedure outlined in GB Patent No. 1,118,176A to Hider et al., which is hereby included by reference. In brief, 2,3-dihydroxypyridine is mixed with an organic halide in a sealed tube and heated at 140°C for 24 hours. The tube is then cooled in an acetone/dry ice bath and opened. The excess halide is poured off and water is added to the dark residue. Sulfur dioxide gas is bubbled through the mixture until the aqueous phase becomes clear. The pH of the reaction mixture is then adjusted to approximately 6 with sodium carbonate, and the resulting solution is extracted with an appropriate solvent after saturation with ammonium sulfate. The organic extracts are dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield a solid which gives the desired N-substituted 3-hydroxypyrid-2-one after crystallization from petroleum ether.


15



20 In particular, 5.6 g of 2,3-dihydroxypyridine in 20 ml of methyl iodide are heated in a sealed tube at 140°C for 24 hours. The tube is cooled in acetone/dry ice, opened and the excess methyl iodide poured off. Distilled water (10 ml) is added and the solution treated with sulfur dioxide until clear. The pH of the reaction mixture is adjusted to 6 with aqueous sodium carbonate (1 M) after which the resulting solution is saturated with ammonium sulfate followed by extraction with chloroform until the chloroform layer fails to give a blue color with aqueous ferric chloride. The combined extracts are dried over sodium sulfate after which the solvent is removed under reduced pressure and the residue crystallized from petroleum ether to give 3-hydroxy-1-methylpyrid-2-one.

25


30



A related compound, 1-ethoxycarbonylmethyl-3-hydroxypyrid-2-one,  
 5 is prepared by heating a mixture of 2,3-dihydroxypyridine (5 g) and 20 ml of  
 ethylbromoacetate in a sealed tube at 140°C for 24 hours, as described by GB Patent  
 No. 4,585,780 to Hider et al., which is hereby incorporated by reference. After  
 cooling in solid CO<sub>2</sub>, the tube is opened, the reaction mixture poured off, and  
 evaporated to dryness under vacuum to yield a yellow solid. Recrystallization from  
 10 water yields the product as white crystals (5.4 g), MP 141-151°C.


By applying the warhead strategy, suitable compounds, e.g. of  
 Formulae (I) or (II), also can be used attached to carriers as defined above, which  
 mimic the substrate motif of the protein hydroxylases. This optimizes the interaction  
 of such compounds with the active site metal ion of these enzymes in order to achieve  
 15 antifibrotic and antiproliferative effects. Carriers can be the physiological substrate  
 motifs in their peptide form, or peptidomimetic molecules of these motifs that are  
 biologically stable and cell membrane permeable. Examples are:

1. A peptide carrier of the substrate motif G-x-y-G-type for  
 inhibition of deoxyhypusyl hydroxylase, to be equipped with an appropriate  
 20 compound of Formulae (I) or (II), such as 1-carboxymethyl-3-hydroxy-2-  
 methylpyrid-4-one or 1-carboxymethyl-3-hydroxypyrid-2-one, respectively. Peptides  
 of the sequence Ac-Dab(A)-H-G-OH, in which A denotes a radical of the Formulae Ia  
 or IIa



are prepared in analogy to the general procedure for synthesis of catecholpeptides as outlined in United States Patent No. 4,797,471 to Teetz et al. which is hereby  
5 incorporated by reference. There, Ac is acetate, Dab is 2,4-diaminobutyric acid, A is a residue constituting a warhead, H is histidine, G is glycine, and OH is hydroxyl. The starting materials are Ac-Dab-H-G-O-Bzl and the 3-benzyloxy derivative of the appropriate hydroxypyridone, all synthesized by conventional methods. The C-terminal substituent '-O-Bzl' is benzyl ester. The peptide and the appropriate 3-  
10 benzyloxyypyridone derivative are coupled using a carbodiimide protocol, i.e., they are dissolved in dimethylformamide in the presence of 1-hydroxybenzotriazole and N-ethylmorpholine, and allowed to proceed at room temperature for 18 hours after addition of dicyclohexylcarbodiimide, as described by U.S. Patent No. 4,797,471 to Teetz et al. The solvent is removed by vacuum, the residue immediately dissolved in  
15 methanol, and, after addition of Pd/C, hydrogenolytically cleaved. When the cleavage is complete, which is checked by thin layer chromatography, the catalyst is removed by filtration, and the filtrate concentrated in vacuo.

2. A peptidomimetic carrier of the substrate motif G-x-y-G for inhibition of deoxyhypusyl hydroxylase, to be equipped with an appropriate moiety of  
20 Formulae (I) or (II), where y indicates the presence of any residue. The  $\beta$ -turn mimetic A



was synthesized according to the method published by Chen et al., Proc. Natl. Acad. Sci. USA 89:5872-5876 (1992), which is hereby incorporated by reference. Briefly,

5 the precursor azetidinone was prepared analogous to Salzmann et al., J. Am. Chem. Soc. 102:6161-63 (1980) and to Williams et al., J. Am. Chem. Soc. 111:1073-83 (1989), which are hereby incorporated by reference. Intermediate reaction steps are:

10 i) mixed anhydride coupling of azetidinone to O-benzyl serine benzyl ester, followed by hydrogenolytic cleavage of the benzyl ester to generate intermediate A; ii) reaction of intermediate A with Z-protected hydrazinophenylalanine, giving intermediate B; iii) using intermediate B, reductive closure, saponification, and hydrogenolytic deprotection of the side chain-protecting groups afforded the product A which was tested to verify its ability to interact as a peptidomimetic with the enzyme (see Fig. 2).

15 For the purposes of using this compound as a carrier, appropriate warheads, e.g. a moiety of Formulae (I) or (II), can be introduced in the course of building up the ring structure A.

The anti-fibroproliferative compounds of the present invention can be used to treat a wide variety of fibrotic disorders. These disorders can be 20 endogenously occurring, e.g. in scleroderma, caused by genetic abnormalities, e.g. in certain forms of neonatal liver fibrosis, due to environmental agents (infectious/occupational/toxic/traumatic), such as in liver cirrhosis or lung fibrosis or post-burn scarring, or the tissue response to medical interventions, such as restenosis of blood vessels after angioplasty, or lung fibrosis after cancer therapy, or scarring 25 after eye surgery. Other disorders include but are not limited to hepatic fibrosis and cirrhosis, renal fibrosis, myelofibrosis, and keloids. These compounds can be administered orally; parenterally, i.e. by subcutaneous, intravenous, or intramuscular injection; intraperitoneally; or by topical application, such as instillation into the walls of blood vessels or hollow organs, or by application to the mucous membranes of the

nose, throat, bronchial tree, or eyes, etc. They may be administered alone or with suitable pharmaceutical carriers, and can be in solid or liquid form such as tablets, capsules, powders, solutions, suspensions, or emulsions. The dosage of the active compound depends on the species of warm-blooded animal, the body weight, age, and mode of administration. Appropriate dosage results in improvement of the clinical disease and, in particular, causes an arrest or a reduction in the mass of the fibrocellular scar tissue or a decrease of the products it secrets, such as the levels of procollagen peptides in serum. The anatomical location of the fibroproliferative scar tissue to be treated is the single most important determinant for the mode of administration and the pharmaceutical preparation of these compounds. Hepatic fibrosis and cirrhosis require an orally active compound rapidly extracted by the liver from the portal blood leaving the gut, which are established pharmacokinetic characteristics of, for instance, a compound like HK1 (CP20,L1, DMHP). Pulmonary fibrosis, on the other hand, is more directly addressed by an intravenously administered agent possibly in combination with inhalation of an aerosolized compound, whereas vascular restenosis or cutaneous scarring can be managed by local application regimen.

The present invention is directed to the treatment of conditions mediated by collagen formation together with cell proliferation. This can involve a condition involving forming new tissues or a condition involving forming new blood capillaries. Examples of such conditions include retinopathies, glomerulopathies, alveolopathies, solid tumor formation, conditions resulting from surgical and non-surgical interventional procedures, and conditions involving vasa vasorum.

The formation of collagens is critical for the biophysical and biochemical integrity of the human body. The collagens also determine morphogenesis in normal and cancerous tissues. They are particularly significant for capillary formation, itself a precondition for the growth of solid tumors beyond a diameter of a few millimeters. In fact, it has been unequivocally established that collagen biosynthesis is a reliable, reproducible, and unbiased index of capillary formation (Maragoudakis, et al., "Validation of Collagenous Protein Synthesis as an Index for Angiogenesis with the Use of Morphological Methods," Microvasc. Res., 50:215-222 (1995), which is hereby incorporated by reference). The involvement of the major fibrillar collagens type I and III is particularly well documented. Type III collagen induces cultured human endothelial cells to form an abundant and branching network of hollow, capillary-like tubes (Kanzawa, et al., "Improved *In vitro* Angiogenesis Model by Collagen Density Reduction and the Use of Type III," Ann.

Plat. Surg., 30:244-251 (1993), which is hereby incorporated by reference). *In vitro*, transcriptional activity of a promoter for type I collagen closely correlates with the formation of capillary-like cords (Fouser et al., "Transcriptional Activity of the Alpha 1 [I]-Collagen Promotor is Correlated with the Formation of Capillary-Like Structures by Endothelial Cell *In vitro*," J. Biol. Chem., 266:18345-18351 (1991); Iruela-Arispe et al., "Modulation of Extracellular Matrix Proteins by Endothelial Cells Undergoing Angiogenesis *In vitro*," Arterioscler. Thromb., 11:805-815 (1991), which are hereby incorporated by reference). Type I procollagen antigenicity in the cells forming sprouting tubes and endothelial cords is markedly enhanced (Iruela-Arispe et al., "Differential Expression of Extracellular Proteins is Correlated with Angiogenesis *In Vitro*," Lab. Invest., 64:174-186 (1991); Jarvelainen et al., "Expression of Decorin by Sprouting Bovine Aortic Endothelial Cells Exhibiting Angiogenesis *In Vitro*," Exp. Cell Res., 203:395-401 (1992); Vernon et al. "Organized Type I Collagen Influences Endothelial Patterns during 'Spontaneous Angiogenesis in vitro': Planar Cultures as Models of Vascular Development," In Vitro Cell. Dev. Biol., 31:120-131 (1995); Sage et al., "Regulation of Angiogenesis by Extracellular Matrix: The Growth and the Glue," J. Hypertens., 12:S145-S152 (1994), which are hereby incorporated by reference).

Formation of any triple helical collagen molecule depends entirely on its hydroxyproline residues. It is remarkable that these basic and functionally so significant residues are not genetically encoded. They are formed only post-translationally from specific proline side chains. These side chains serve as substrates for the enzyme prolyl 4-hydroxylase. The formed hydroxyproline residues, which almost exclusively occur in collagenous proteins, anchor a sheet of water molecules that wrap around each trimer like an externally stabilizing cylinder, imparting a rod-like structure. Consequently, inhibition of prolyl 4-hydroxylase should trigger a cascading series of events that, in the end, disrupt the angiogenic pathway: the lack of hydroxyproline should result in deficiency of native, triple helical collagens regardless of type. This deficiency, in turn, should affect all collagen-dependant steps of capillary formation. Interference with prolyl hydroxylation indeed has marked anti-angiogenic consequences *in vitro* (Nicosia et al., "Regulation of Angiogenesis *In Vitro* by Collagen Metabolism," In Vitro Cell. Dev. Biol., 27A:961-966 (1991); Ingber et al., "Inhibition of Angiogenesis through Modulation of Collagen Metabolism," Lab. Invest., 59:44-51 (1988), which are hereby incorporated by reference) and *in vivo* (Haralabopoulos et al., "Inhibitors of Basement Membrane Collagen Synthesis Prevent Endothelial Cell Alignment in Matrigel *In Vitro* and

Angiogenesis *In Vivo*," Lab. Invest., 71:575-582 (1994), which is hereby incorporated by reference), e.g., in rats carrying the Walker 256 carcinosarcoma (Maragoudakis et al., "Basement Membrane Biosynthesis as a Target for Developing Inhibitors of Angiogenesis with Anti-Tumor Properties," Kidney Int., 43:147-150 (1993), which is hereby incorporated by reference).

5           Endothelial cells ("EC") can respond to specific signals and initiate a process of new blood vessel formation (i.e., capillary formation) that involves endothelial cell proliferation, degradation, invasion, and migration into tissue, and collagen synthesis to form a new blood vessel. Thus, the proliferation of endothelial cells and their 10 subsequent ability to synthesize collagen are two processes required for capillary formation. Endothelial cell proliferation is observed in the new vessels that are formed during the hypertrophy of the endometrium during the normal menstrual cycle (Kooy et al., "Endothelial Cell Proliferation in the Endometrium of Women with Menorrhagia and in Women Following Endometrial Ablation," Hum Reprod., 15 11:1067-72 (1996), which is hereby incorporated by reference). Collagen synthesis is required for 2 reasons: 1) it appears that endothelial cells migrate along a collagenous fibril in the luminal space in order to form the new vessel, and 2) the new vessel depends upon synthesis of a basement membrane, composed of collagen, on its abluminal (i.e., basilar) surface.

20           The pharmaceutical products of the present invention are prepared by dissolving, mixing, granulating, or tablet-coating processes which are known per se.

25           For oral administration, the active compounds or their physiologically tolerated derivatives such as salts, esters, or amides, are mixed with the additives customary for this purpose, such as vehicles, stabilizers, or inert diluents, and converted by customary methods into a suitable form for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic, or oily suspensions, or aqueous, alcoholic or oily solutions. Examples of suitable inert vehicles are conventional tablet bases such as lactose, sucrose, or cornstarch in combination with binders like acacia, cornstarch, gelatin, or with disintegrating agents 30 such as cornstarch, potato starch, alginic acid, or with a lubricant like stearic acid or magnesium stearate. Examples of suitable oily vehicles or solvents are vegetable or animal oils, such as sunflower oil or fish-liver oil. Preparations can be effected both as dry and as wet granules.

35           For parenteral administration (subcutaneous, intravenous, intraarterial, or intramuscular injection), the active compounds or their physiologically tolerated derivatives such as salts, esters, or amides, are converted into a solution, suspension

or emulsion, if desired with the substances customary and suitable for this purpose, such as solubilizers or other auxiliaries. Examples are: sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions.

5

For use as aerosols, the active compounds or their physiologically tolerated derivatives such as salts, esters, or amides, may be dissolved or suspended in a physiologically acceptable liquid and packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. The antifibrotic agents may also be administered from a non-pressurized container such as a nebulizer or atomizer.

10

For topical administration to external or internal body surfaces, e.g. in the forms of creams, gels, or drops, etc., for treatment of fibroproliferative conditions involving, for instance, the skin or the eye, the active compounds or their physiologically tolerated derivatives such as salts, esters, or amides, are prepared and applied as solutions, suspensions, or emulsions in a physiologically acceptable diluent with or without a pharmaceutical carrier.

15

### Examples

#### **General Methodology**

25

The inhibitory action of the substances according to the invention, for example on collagen secretion or cell proliferation, can be tested in direct assays of the enzymes mediating the pivotal protein hydroxylations for these biological processes, such as prolyl 4-hydroxylase and deoxyhypusyl hydroxylase. This entails the enzymatic hydroxylation of the appropriate protein precursor, either by the cellular or the purified enzyme, in the presence or absence of compounds of Formulae (I) or (II), with concomitant determination of co-substrate utilization by these enzymes or subsequent isolation of the hydroxylated amino acid and its unhydroxylated precursor. In this manner, the inhibitory potency of any given compound can be measured in the cell-free system, in cell culture, or in tissue, and is expressed as the inhibitory dose that gives a 50% reduction of the enzyme-mediated


30

35

reaction (ID50). Enzyme is tested in analogy to the method of A. Abbruzzese, H.M. Hanauske-Abel, et al., Biochem. Biophys. Acta, 1077, 159 - 166 (1991) and of K. Majamaa, H.M. Hanauske-Abel, et al., Eur. J. Biochem. 138, 239 - 245 (1984), which are hereby incorporated by reference. Table III lists the ID50 values of some of the compounds according to the invention, using purified human prolyl 4-hydroxylase and cellular human deoxyhypusyl hydroxylase as representative protein hydroxylases.

TABLE III

10



|               | R1  | R2                               | Prolyl 4-   | Deoxyhypusyl |
|---------------|---|----------------------------------|-------------|--------------|
|               |   |                                  | hydroxylase |              |
| L-Mimosine    | -CH <sub>2</sub> CH(NH <sub>2</sub> )COOH                             | H                                | 120         | 65           |
| - ethyl ester | -CH <sub>2</sub> CH(NH <sub>2</sub> )COOC <sub>2</sub> H <sub>5</sub> | H                                | 145         |              |
| HK-1          | -CH <sub>3</sub>  | -CH <sub>3</sub>                 | 133         | 90           |
| HK-2          | -CH <sub>2</sub> CH <sub>3</sub>                                      | -CH <sub>2</sub> CH <sub>3</sub> | 145         | 50           |
| HK-15         | -CH <sub>2</sub> OCH <sub>2</sub> CH <sub>3</sub>                     | -CH <sub>3</sub>                 | 210         | 60           |
| HK-16         | -CH <sub>2</sub> CH=CH <sub>2</sub>                                   | -CH <sub>3</sub>                 | 150         | 50           |
| HK-26         | -CH <sub>2</sub> CH <sub>3</sub>                                      | -CH <sub>3</sub>                 | 130         | 58           |
| HK-27         | -(CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>                      | -CH <sub>3</sub>                 | 155         | 50           |

15

The examples which follow serve to illustrate the present invention without intending to restrict it to them.

#### Example 1 - Inhibition of purified human prolyl 4-hydroxylase

20

The inhibiting effect of hydroxypyridones on the collagen-hydroxylating enzyme was studied in a cell-free system.

## Methods

### Assay of purified human prolyl 4-hydroxylase

5           The native  $\alpha_2\beta_2$ -tetrameric enzyme was purified to homogeneity by poly(L-proline) affinity chromatography and DEAE chromatography from the supernatant of *Spodoptera frugiperda* insect cells cotransfected with recombinant baculovirus transfer vectors for both the human  $\alpha$ - and  $\beta$ -subunits. Enzyme activity was determined by trapping of  $^{14}\text{CO}_2$  released from 2-oxo[1- $^{14}\text{C}$ ]glutarate] according to the procedure of Majamaa, et al., *Eur. J. Biochem.*, 138:239-245 (1984), which is hereby incorporated by reference. Briefly, all incubations were run for 60 minutes at 10 37°C in a final volume of 1.0 ml per test sample, containing 0.1  $\mu\text{g}$  enzyme, 0.1 mg heat-denatured (Pro-Pro-Gly)<sub>10</sub> x 9 H<sub>2</sub>O as hydroxylatable substrate, 0.1 mM 2-oxo[1- $^{14}\text{C}$ ]glutarate] adjusted to 60,000 dpm by mixing with the unlabeled 2-oxoglutarate as cosubstrate, and cofactors (1.6 mM ascorbate, 0.05 mM ferrous sulfate, 0.08 mM dithiothreitol, 2 mg bovine serum albumin, 5  $\mu\text{L}$  catalase). Assays 15 are performed with only one of the active compounds at any given time.

## Results

20

All of the seven representative hydroxypyridone compounds were found to be potent prolyl 4-hydroxylase inhibitors (Fig. 1). It is prior established knowledge that suppression of prolyl 4-hydroxylase leads to an inability of collagen proteins to form their biologically active structure, the characteristic 'collagen triple helix', and leads to reduced collagen secretion and/or extracellular collagen fibril formation, i.e., leads to a reduction of the fibrous component within fibroproliferative scar tissue. The actual effect of representative hydroxypyridones on secretion of collagens prominent in the scarring process, collagens type I and III, was subsequently examined in cultured human cells known to be causally involved in 25 fibroproliferative diseases.

### Example 2 - Inhibition of purified rat deoxyhypusyl hydroxylase

30           The inhibiting effect of a model peptidomimetic, suitable to serve as carrier for hydroxypyridone warheads, on the activity of the purified eIF-5A-hydroxylating enzyme was studied in a cell-free system.

**Methods****DOHH Assay**

5                   Enzyme activity was purified and determined as described by  
Abbruzzese et al., *J. Biol. Chem.* 261:3085-9 (1986), which is hereby incorporated by  
reference. Briefly, the enzyme is offered labeled deoxyhypusine-containing eIF-5A  
precursor. Following standard incubation conditions, the conversion into hypusine  
residues is measured by chromatographic amino acid separation after protein  
10                   hydrolysis.

**Results**

15                   Mimetic A was designed, and then synthesized, to covalently stabilize  
the optimal  $\beta$ -turn conformation known to be characteristic for -G-x-y-G- motifs  
when occurring within the structure of the native substrate proteins of deoxyhypusyl  
hydroxylase or the collagen hydroxylases. At the same time, mimetic A lends itself to  
serve as a carrier for a reactive moiety to be positioned at the hydroxylation site for  
interaction with the active site metal ion. In the case of mimetic A, this reactive  
20                   moiety can be attached at the site indicated by the asterisk in Fig. 2.

25                   The effect of mimetic A on the hydroxylation of -G-x-y-G-containing  
proteins was studied using unhydroxylated eIF-5A precursor and purified  
deoxyhypusyl hydroxylase. As shown in Fig. 2, the deoxyhypusine-to-hypusine  
conversion is suppressed by the presence of mimetic A, i.e., formation of the  
hydroxylated form is inhibited while the unhydroxylated precursor is not utilized.  
Mimetic A is only weakly inhibitory itself, but can be used to carry, positioned at the  
site of the asterisk in Figure 2, a "warhead" moiety of Formulae (I) or (II).

**Example 3 - Inhibition of cellular human deoxyhypusyl hydroxylase**

30                   The inhibiting effect of hydroxypyridones on the eIF-5A-  
hydroxylating enzyme was studied in cultured human cells (i.e. smooth muscle cells,  
B-lymphocytes).

**Methods****DOHH Assay**

5                   The cellular conversion of the precursor deoxyhypusine to the hydroxylated hypusine in cells was examined, after preincubation with the inhibitor for 60 minutes, by labeling the human cells with  $^3\text{H}$ -spermidine (5  $\mu\text{Ci}/\text{ml}$ ) in 25  $\text{cm}^2$  flasks ( $1 \times 10^6$  cells/flask) for 24 hours prior to cell lysis, precipitation with 10% TCA containing 1 mM each of putrescine, spermidine, and spermine, and hydrolysis in 6 N 10 HCl at 110°C for 16 hours. The hydrolysate was analyzed for labeled amino acids on an amino acid analyzer by published methods (Park et al., *J. Biol. Chem.*, 257:7217-7222 (1982), which is hereby incorporated by reference). The retention of purified hypusine and deoxyhypusine was determined from standards.

15                   **Results**

20                   L-Mimosine is known to be a reversible inhibitor of the multiplication of certain cells, which is temporally associated with its ability to block the cellular deoxyhypusyl hydroxylase activity required to produce the active protein synthesis initiation factor eIF-5A (Hanauske-Abel et al., *Biochem. Biophys. Acta*, 1221:115-124 (1994), which is hereby incorporated by reference). The results presented in Fig. 3 indicate that L-mimosine and other representative hydroxypyridones also inhibit deoxyhypusyl hydroxylase activity in human smooth muscle cells (Figure 3b) and in human B-lymphocytes (Figure 3a).

25

**Example 4 - Inhibition of prolyl 4-hydroxylase in scar tissue-producing human cells obtained from blood vessels and lung**

30                   The selective inhibition of collagen secretion by illustrative hydroxypyridones was established in cultured human cells known to be causally linked to typical fibroproliferative diseases. The human cells used, vascular smooth muscle cells and lung fibroblasts, are generally believed to mediate all forms of vascular fibrosis and all forms of pulmonary fibrosis, respectively.

35

**Methods****Cell Culture**

5

***A. Vascular smooth muscle cells.***

10

Human coronary artery smooth muscle cells ("SMC") were isolated from specimens collected immediately after directional rotary atherectomy (Simpson AtheroCath, DVI, Inc., Redwood City, CA). A portion of the tissue was fixed in 10% buffered formalin for histology, and the remaining tissue was finely diced and placed onto collagen-coated (Vitrogen, Collagen Corp., Palo Alto, CA) flasks in Medium 199 containing 20% fetal bovine serum ("FBS") and gentamycin sulfate (50  $\mu$ g/ml, Gibco, Grand Island, NY). Cells migrating from the explants were subpassaged with trypsin/EDTA and used within the first 5 passages. Cell cultures were obtained from primary atherosclerotic and from restenotic lesions. To verify the SMC phenotype of the cultures, cells were plated onto LabTek 8-chamber slides and stained by indirect immunofluorescence for the SMC marker contractile  $\alpha$ -actin, using a mouse monoclonal antibody specific for the contractile smooth muscle  $\alpha$ -actin (clone No. 1A4; Sigma) which was detected with FITC- or peroxidase-labeled mouse immunoglobulins (Sigma). Non-immune mouse serum was used as a control. Results were photodocumented with a Nikon Labophot 2 fluorescence microscope.

20

***B. Lung fibroblasts.***

25

The established human lung fibroblast line MRC-5 was used, maintained, and propagated by routine cell culture techniques.

**Assay of cellular human prolyl 4-hydroxylase**

30

SMC or MRC-5 cells ( $3-5 \times 10^6$  cells/35 mm well) were labeled in the presence or absence of hydroxypyridones, with  $^3$ H-proline (Pro) (4  $\mu$ Ci/ml) for 24 hours in proline- and serum-free Dulbecco Minimal Essential Medium ("DMEM") containing 50  $\mu$ g/ml sodium ascorbate and 20  $\mu$ g/ml  $\beta$ -aminopropionitrile. Supernatants and cells were precipitated in 10% TCA, hydrolyzed (6 N HCl, 110°C, 16 hours) and lyophilized, as described by G. Tschanck, H.M. Hanuske-Abel and collaborators, *Biochem. J.* 248:625 - 633 (1987), which is hereby incorporated by reference. The hydrolysate was derivatized with phenylisothiocyanate and analyzed for  $^3$ H-proline ("Pro") and  $^3$ H-hydroxyproline ("Hyp") by HPLC on a reverse-phase

35

C18 column, using an automated HPLC system (Hewlett-Packard, Wilmington, DE) with an in-line scintillation counter (Inus Systems, Inc., Tampa, FL). The position of proline and hydroxyproline was determined from tritiated standards.

5 **Plasminogen activator inhibitor assay**

Supernatants of human SMC incubated with the hydroxypyridone L-mimosine under serum-free conditions (to avoid plasma-derived inhibitors) were tested for their ability to inhibit a standard amount of urokinase-type plasminogen activator (uPA) in the presence of plasminogen and the fluorometric peptide plasmin substrate d-Val-Leu-Lys-aminomethylcoumarin (Enzyme Systems, Livermore, CA). Inhibition of plasmin generation was compared to a standard curve of human PAI-1 (American Diagnostica, Greenwich, CT) to yield PAI-1 activity.

15 **Determination of type I and type III procollagen biosynthesis**

SMC or MRC-5 cells ( $3-5 \times 10^6$  cells/35 mm well), incubated in serum-free DMEM containing 50  $\mu$ g/ml sodium ascorbate and 20  $\mu$ g/ml  $\beta$ -aminopropionitrile, are exposed for 24 hours to increasing concentrations of hydroxypyridones. After centrifugation, to clear any cellular debris, these supernatants are used to determine the levels of type I and III procollagens, using commercially available radioimmunoassays (Incstar and Behringwerke, respectively).

25 **Determination of Type I and Type III Procollagen Biosynthesis**

Human SMC ( $3-5 \times 10^5$  cells/35 mm well), grown to confluence and incubated in serum-free DMEM containing 50  $\mu$ g/ml sodium ascorbate and 20  $\mu$ g/ml  $\beta$ -aminopropionitrile, were exposed for 24 hours to increasing concentrations of test compounds. After centrifugation to clear any cellular debris, these supernatants were used to determine the levels of type I and III procollagens. Type I procollagen biosynthesis also was quantified by Western analysis in the following manner. Supernatants were precipitated with 10% TCA and electrophoresed under non-reducing conditions on a 4-20% SDS-PAGE gel. The gel was transferred to nitrocellulose with a semi-dry blotter (Bio-Rad, Hercules, CA). The membrane was blocked with 1% goat serum / 1% bovine serum albumin and then incubated with a 1:200 dilution of a rabbit polyclonal antiserum (LF41) against a 21 amino acid synthetic peptide homologous to the C-terminal sequence of the C-propeptide of the

component  $\alpha 1$  chain of human type I procollagen. Because in each type I procollagen molecule two of these globular domains are disulfide-linked to the C-terminal globular domain of one component  $\alpha 2$  chain, this antibody can be used under non-reducing conditions to detect trimeric, native C-propeptide proteolytically released during procollagen-collagen conversion. Non-immune rabbit serum was used as a control. Immunoblots were scanned with a UMAX UC630 flatbed scanner and quantified densitometrically using standard software.

## Results

10

A high percentage (30-40%) of cultured SMC spontaneously showed strong reactivity toward the anti- $\alpha$ -actin antibody, and essentially all cells became  $\alpha$ -actin positive upon serum-withdrawal and treatment with transforming growth factor- $\beta 1$ (<1 ng/ml), consistent with the behavior of normal SMCs [Bjorkerud et al., 15 Arteriosclerosis, 11:892-202 (1991)] or myofibroblasts [Desmouliere et al., Cell Biol., 122:103-111 (1993); Ronnov-Jessen et al., Lab. Invest., 68:696-707 (1993), which are hereby incorporated by reference]. The characteristic microscopic appearance of SMC after immunostaining for  $\alpha$ -actin is shown in Fig. 4b. The cultured MRC-5 cells had the typical morphology of fibroblasts.

20

In these lesion-derived human SMC, the hydroxypyridone L-mimosine was able to selectively suppress hydroxyproline ("Hyp") formation by 80-90% whereas proline ("Pro") incorporation, an index of general protein synthesis, was reduced by less than 20% of controls (Fig. 4a). This indicates that L-mimosine quite selectively inhibits collagen hydroxylation, with minimal if any consequence for the 25 overall synthesis of cellular proteins. Furthermore, the suppression of cellular prolyl hydroxylase activity by L-mimosine was rapidly reversible upon removal of the inhibitor. L-Mimosine also selectively inhibited the secretion of hydroxyproline-containing proteins by human lung fibroblasts. The discriminately suppressive effect by other illustrative hydroxypyridones on collagen secretion by these cells is 30 evidenced in Fig. 5.

Selectivity for inhibition of just collagen secretion by SMC was also demonstrated when secreted proteins were determined individually. Three representative molecules excreted by vascular SMC were measured:

35

- the amino-terminal propeptide of type III procollagen, a marker of the fibrotic changes in atherosclerosis (Bonnet et al., Eur. J. Clin. Invest., 18:18-21 (1988), which is hereby incorporated by reference);

- the carboxy-terminal propeptide of type I procollagen, a collagen expressed by SMC after vascular injury *in vivo* (Majesky et al., *J. Clin. Invest.*, 88:904-910 (1991), which is hereby incorporated by reference);  
5 (NOTE: The procollagen propeptides are globular domains cleaved from the procollagen molecule after its secretion by the action of specific extracellular proteinases prior to collagen fibril formation, and thus are markers for extracellular collagen deposition.)
- plasminogen activator inhibitor-1 ("PAI-1"), a modulator of blood coagulation.  
10

15 The results indicate that L-mimosine was a potent inhibitor of the secretion of procollagen types I and III. In contrast, the secretion of the non-collagenous protein, plasminogen activator inhibitor-1 ("PAI-1") was not affected by L-mimosine treatment (Figure 6).

20 **Example 5 - Reversible inhibition of vascular cell proliferation:  
smooth muscle cells**

25 The selective inhibition of cell proliferation by illustrative hydroxypyridones was established in cultured human SMC obtained from fibroproliferative vascular lesions as described before.

25 **Methods**

25 **Cell Proliferation**

30 Inhibition of DNA synthesis was examined by semiautomated methods. SMC were plated at  $1 \times 10^4$  cells/well in 96-well microtiter plates at least 24 hours prior to the assay. Agents were introduced into normal serum-containing growth media for 20 hours before the cells were pulsed with  $^3\text{H}$ -thymidine (1  $\mu\text{Ci}/\text{ml}$ ) for 4 hours. Cells were collected with a cell harvester and the DNA-incorporated label determined by scintillation counting (Betaplate; Wallac, Inc., Gaithersburg, MD) (n=6 per point).

### Results

5 All hydroxypyridones were potent inhibitors of DNA synthesis in lesion-derived SMC. SMC obtained from both primary atherosclerotic and restenotic lesions were equally susceptible. To rule out toxicity-induced loss of viability, the reversibility of this effect was investigated. The cytostatic effect was fully reversible upon withdrawal of the compounds when corrected for cell number, as shown in Fig. 7 for the hydroxypyridone mimosine. After an initial 24-hour treatment, DNA synthesis was inhibited by L-mimosine, but not by the hydroxypyridone analog kojic acid. Following inhibitor removal and an additional 24-hour recovery period, there was a marked rebound effect on DNA synthesis in L-mimosine-arrested cells, but not in kojic acid-treated cells. This finding is consistent with synchronous release of a large cohort of SMC from a L-mimosine-sensitive arrest point, as observed in other cell types (Hanauske-Abel et al., *Biochem. Biophys. Acta* 1221:115-124 (1994),  
10 which is hereby incorporated by reference).

15

### **Discussion**

20 The body's response to any kind of real or perceived tissue damage consists of the activation of two major biochemical pathways, one resulting in the proliferation of cells, the other in the deposition of extracellular matrix at the site of the inciting event. The biological outcome of both coordinated pathways is the local formation of a fibrocellular tissue that usually serves to repair any lesion and to reconstruct physical integrity. This basic response is, however, often itself the cause  
25 for progressive loss of function, particularly, if this response causes disruption of the normal anatomy by scar tissue. Such a scarring (i.e., its fibroproliferative component) is a critical element of all human chronic diseases and is the key outcome-determining event in, for instance, liver cirrhosis, lung fibrosis, or restenosis of occluded blood vessels after interventional therapy.

30 To this day, cell proliferation and matrix formation are generally considered to be two interrelated, but disparate biological processes, with no common single chemical event controlling their execution. However, such a common single chemical event does exist. Cell proliferation and matrix formation each critically depend on the hydroxylation of specific proteins. Surprisingly, inhibitors of this common chemical event that block the scar-formation-mediating protein hydroxylases and thus have anti-fibroproliferative effects are identified. A general strategy for the  
35

further, rational design of such agents also has been formulated. This strategy centers on the combination of two molecular fragments, one imitating the substrate motif of the protein hydroxylases ("carrier"), the other one ("a warhead") consisting of a moiety able to interact with the active site metal of these enzymes. While each

5 fragment by itself is not an efficient inhibitor, their combination into one agent by appropriate coupling, provides a superior agent for inhibition of protein hydroxylase activity ("warhead strategy"). Variations of carriers and warheads can be made by those skilled in the art guided by the warhead strategy, without departing from the spirit and scope of this strategy.

10 One class of warheads might be selected from agents that by themselves are able to interact with metal ions in solution (i.e. chelators). In this manner, the metal-dependent protein hydroxylases are depleted of their actual catalyst. However, the metal binding capacity of chelators does not determine, or correlate with, their ability to inhibit the protein hydroxylases. For instance, it was demonstrated for deoxyhypusyl hydroxylase that less efficient chelators achieved higher inhibitory effectiveness, indicating that a warhead must be able to reach physically the active site metal center, or otherwise is excluded from access by protein-imposed ionic and steric restrictions, as shown by Abbruzzese, Hanauske-Abel et al., Biochim. Biophys. Acta 1077:159-166 (1991), which is hereby

15 incorporated by reference. Similarly, exposure of cells to metal chelators does not per se result in any antiproliferative effect. For instance, exposure to the chelator pyridoxal isonicotinyl hydrazone even stimulates the proliferation of certain human cells. See Ekblom et al., Scand. J. Haematol. 36:258-262 (1986), which is hereby incorporated by reference. Consequently, the highly selective inhibitory effect of

20 metal-binding warheads, like the compounds of Formulae (I) and (II), on protein hydroxylation-related events and not, for instance, on protein synthesis in general, is surprising.

25

It has been noted before that the protein hydroxylases share common features, such as the use of similar substrate motifs by prolyl 4-hydroxylase and deoxyhypusyl hydroxylase. However, this does not mean that inhibitors identified for one of these enzymes will also inhibit the other enzymes, such as inhibitors structurally suited to bind the active site metal of these enzymes. For example, pyridine-2,4-dicarboxylate, which binds to the active site metal ion of prolyl 4-hydroxylase and, consequently, is an excellent inhibitor of collagen formation, as described by Majamaa, Hanauske-Abel et al., Eur. J. Biochem. 138:239-245 (1984), which is hereby incorporated by reference, is non-inhibitory for deoxyhypusyl

hydroxylase, as determined by Abbruzzese et al., J. Biol. Chem. 261:3085-9 (1986), which is hereby incorporated by reference. Likewise, certain catecholpeptides have been identified as competitive, potent inhibitors of purified deoxyhypusyl hydroxylase but were found to be only weak or non-competitive inhibitors for prolyl 4-hydroxylase (Abbruzzese, Hanauske-Abel, et al., Biochim. Biophys. Acta, 1077:159 - 166 (1991), which is hereby incorporated by reference), reemphasizing the distinct active site organization of each protein hydroxylase. Consequently, the discovery that a single class of agents simultaneously and potently inhibits both prolyl 4- and deoxyhypusyl hydroxylase, whether purified or in cells, is surprising and points to a unique effect of these agents on the formation of the hydroxylated amino acid residues.

In collagens, the crucial hydroxylated residues are *trans* -4-hydroxyprolines, formed post-translationally by prolyl 4-hydroxylase. This enzyme, an  $\alpha_2\beta_2$ -tetrameric, divalent iron-containing dioxygenase, stoichiometrically utilizes 2-oxoglutarate and molecular oxygen for the stereospecific hydroxylation of a sequence-defined proline residue, generating equimolar quantities of carbon dioxide, succinate, and peptidyl *trans* -4-hydroxyproline. One atom of molecular oxygen appears in the hydroxyl group, the other one in the 2-oxoglutarate-derived succinate (Kivirikko et al., FASEB J., 3:1609-1617 (1989), which is hereby incorporated by reference). Ascorbate is not consumed stoichiometrically, and the catalytic cycle proceeds even in its absence (Myllyla et al., J. Biol. Chem., 259:5403-5405 (1984), which is hereby incorporated by reference). The stereochemical concept for the mechanism of prolyl 4-hydroxylase, published in 1982 by Hanauske-Abel and Gunzler (J. Theor. Biol., 94:421-455 (1982), which is hereby incorporated by reference), was the first to accommodate these complex findings and since then has been used successfully to guide the development of inhibitory 2-oxoglutarate analogs. Suppression of prolyl 4-hydroxylation prevents the formation of the collagenous triple helix which is entirely dependent on *trans* -4-hydroxyproline residues and is required for the secretion and processing of at least the interstitial procollagens. In this way, inhibition of prolyl 4-hydroxylase markedly and selectively reduces formation of the extracellular matrix (Hanauske-Abel, J. Hepatol., 13 (suppl.):s8-s15) (1991), which is hereby incorporated by reference).

In eIF-5A, this unique hydroxylated amino acid residue is hypusine [ $\text{Ne}-(4\text{-amino-2(R)-hydroxybutyl})\text{lysine}$ ]. The synthesis of active eIF-5A involves two distinct post-translational modifications: i) the  $\text{NAD}^+$ - dependent transfer of a spermidine-derived 4-aminobutyl moiety onto the  $\epsilon$ -amino group of a

sequence-defined lysine residue, generating deoxyhypusine (Wolf et al., J. Biol. Chem., 265:4793-4799 (1990), which is hereby incorporated by reference); and ii) the stereospecific hydroxylation of carbon 9 by the metallo-enzyme deoxyhypusyl hydroxylase, generating hypusine (Abbruzzese et al., J. Biol. Chem., 261:3085-3089 (1986), which is hereby incorporated by reference). eIF-5A contains a single hypusine residue that has not been identified in any other protein (Park et al., Bio Factors, 4:95- 104 (1993), which is hereby incorporated by reference). Inhibition of hypusine formation correlates with reversible arrest of cell proliferation, apparently by selectively inhibiting polysomal production of certain proteins indispensable for the onset of DNA replication, thereby causing the reversible accumulation of cells in the late G1 phase of the cell cycle (Hanauske-Abel et al., Biochim. Biophys. Acta 1221: 115-24, (1994), which is hereby incorporated by reference).

As the collagens do not contain hypusine and as eIF-5A lacks hydroxyproline, it would not have been expected that inhibition of just one of the protein hydroxylases could by itself produce an anti-fibroproliferative effect. In fact, experimental evidence suggests that cross-over inhibition of proliferation does not occur if collagen hydroxylation is directly and selectively suppressed: the potent prolyl 4-hydroxylase antagonists pyridine 2,4-dicarboxylate and pyridine 2,5-dicarboxylate (Majamaa et al., Eur. J. Biochem., 138:239- 245 (1984), which is hereby incorporated by reference), which lack the ability to inhibit deoxyhypusyl hydroxylase (Abbruzzese et al., J. Biol. Chem., 261:3085-3089 (1986), which is hereby incorporated by reference), do not affect cell proliferation or cell cycle transit.

The single most important cellular protein hydroxylases determining collagen secretion and cell proliferation, prolyl 4-hydroxylase and deoxyhypusyl hydroxylase, respectively, are each inhibited by compounds of Formulae (I) or (II) in a dose-dependent manner (Table II). The hydroxypyridones L-mimosine and HK1, DMPH, for instance, directly inhibit prolyl 4-hydroxylase (Fig. 1) and deoxyhypusyl hydroxylase (Fig. 3) when assayed *in vitro*. The inhibition of each cellular protein hydroxylase has been shown before to halt the secretion of *de novo* synthesized collagens (Hanauske- Abel, J. Hepatol., 13 (suppl. 3):s8-s15) (1991), which is hereby incorporated by reference) and to arrest the onset of DNA synthesis, respectively (Hanauske-Abel et al., Biochim. Biophys. Acta 1221: 115-24 (1994), which is hereby incorporated by reference), a finding corroborated by the incorporation of radiolabeled precursors (Figs. 4,5,7). Each of these suppressive effects was reversible upon removal of L-mimosine and HK1, respectively, and did not result from non-specific or toxic effects (Figs. 6,7).

**Example 6 - Inhibition of Vascular Cell Proliferation: Endothelial Cells**

Endothelial cell proliferation was determined by essentially the same methods previously disclosed for the determination of smooth muscle proliferation. Human umbilical vein endothelial cells ("HUVEC") were isolated and subcultured in Medium 199 containing 15% fetal bovine serum ("FBS"), endothelial cell growth factor ("ECGF", 5 ng/ml), heparin (9  $\mu$ g/ml), and antibiotics. The cells were plated in 96-well dishes at  $1 \times 10^4$  cells per well and then allowed to attach for 24 hours. The medium was removed, and the cells were changed to media containing deferiprone at 50, 100, 200, or 500  $\mu$ M. After 24 hours, tritiated thymidine was added to the wells and allowed to incorporate into the DNA for 4 hours prior to isolation of the nuclear DNA by standard methods. The results are expressed as the counts per minute ("cpm") of radioactivity per well, which is proportional to the rate of DNA synthesis during the 4 hour labelling period.

The results, as shown in Figure 9, demonstrates that deferiprone blocks the proliferation of endothelial cells ("EC") cultured from human umbilical cords, while kojic acid, a metal chelator that does not inhibit protein hydroxylases, does not inhibit EC proliferation. Proliferation was evaluated by the incorporation of tritiated thymidine into cellular DNA after 24 hours of treatment with drug.

**Example 7 - Inhibition of Capillary (tube) Formation**

Endothelial cell tube formation was determined by plating HUVEC on a thick Matrigel (Becton Dickinson Labware) gel at a density of  $5 \times 10^4$  cells per well of 24 well dish. Deferiprone was incubated with the cells for 30 minutes in solution prior to applying the cells to the Matrigel. The cells were added to the Matrigel-coated well, and, then 4 hours and 24 hours later, the cells were observed and photographed at a reproducible location.

The results of the *in vitro* tube formation assay demonstrates that deferiprone blocks the formation of tubular structures resembling blood vessels that are formed by EC when placed on Matrigel. See the photographs of the endothelial cells 24 hours after treatment in Figure 10. Figure 10A shows that untreated HUVEC form capillary-like tubes, while deferiprone-treated cells (see Figure 10B) do not form tubes, but remain healthy and viable in appearance.

### Discussion of Examples 6 and 7

The present invention shows that an inhibitor of protein hydroxylases (e.g., deferiprone) can also block capillary formation in *in vitro* models of vessel formation. The present examples demonstrate that deferiprone can inhibit endothelial cell proliferation, when measured by a standard thymidine incorporation assay. Further, it is shown that deferiprone can block the formation of capillary-like structures (i.e., tubes) that EC form when placed upon a particular extracellular matrix called Matrigel.


This Matrigel capillary formation model is an accepted *in vitro* model of capillary formation which depends principally upon EC migration and collagen synthesis and does not depend strongly upon EC proliferation. Prior studies have shown that agents that inhibit capillary formation in the Matrigel model also inhibit capillary formation *in vivo* (Haralabopoulos et al., "Inhibitors of Basement Membrane Collagen Synthesis Prevent Endothelial Cell Alignment in Matrigel *In Vitro* and Angiogenesis *In Vivo*," Lab. Invest., 71:575-582 (1994); Maragoudakis et al., "Basement Membrane Biosynthesis as a Target for Developing Inhibitors of Angiogenesis with Anti-Tumor Properties," Kidney Int., 43:147-150 (1993), which are hereby incorporated by reference). It has been shown that some agents that block collagen synthesis can block capillary formation in the Matrigel model (Haralabopoulos et al., "Inhibitors of Basement Membrane Collagen Synthesis Prevent Endothelial Cell Alignment in Matrigel *In Vitro* and Angiogenesis *In Vivo*," Lab. Invest., 71:575-582 (1994), which is hereby incorporated by reference), supporting the premise that collagen synthesis is an important mechanism of capillary formation.

The above results indicate that deferiprone blocks capillary formation by jointly inhibiting cell proliferation and collagen synthesis.

Although the invention has been described in detail for the purposes of illustration, it is understood that such detail is solely for that purpose, and variations can be made by those skilled in the art without departing from the spirit and scope of the invention that is defined by the following claims.

**WHAT IS CLAIMED:**

1. A method of treating conditions mediated by collagen formation together with cell proliferation in living systems comprising:  
5 administering to living systems an amount of a compound of formulas I and II and their salts, esters, or amides effective to treat the condition mediated by collagen formation together with cell proliferation as follows:



10

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 15 10 to about 30 carbon atoms, wherein the compound is not mimosine.

20 2. A method according to claim 1, wherein the living system is a mammalian subject.

3. A method according to claim 1, wherein the living system is cells in an *in vitro* system.

25 4. A method according to claim 1, wherein the condition being inhibited is a collagen- and proliferation-dependent process of forming new tissues.

5. A method according to claim 1, wherein the condition being inhibited is a collagen- and proliferation-dependent process of forming new blood capillaries.

5 6. A method according to claim 1, wherein the condition being inhibited is selected from the group consisting of retinopathies, glomerulopathies, alveolopathies, solid tumor formation, conditions resulting from surgical and non-surgical interventional procedures, and conditions involving vasa vasorum.

10 7. A method according to claim 1, wherein R<sub>2</sub> is H or an alkyl group with up to 2 carbon atoms and R<sub>3</sub> and R<sub>4</sub> is H or methyl.

15 8. A method according to claim 7, wherein R<sub>1</sub> and R<sub>2</sub> are methyl and R<sub>3</sub> and R<sub>4</sub> are H.

9. A method according to claim 7, wherein R<sub>1</sub> is CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, R<sub>2</sub> is methyl, and R<sub>3</sub> and R<sub>4</sub> are H.

20 10. A method according to claim 7, wherein R<sub>1</sub> is CH<sub>2</sub>CH=CH<sub>2</sub>, R<sub>2</sub> is methyl, and R<sub>3</sub> and R<sub>4</sub> are H.

11. A method according to claim 7, wherein R<sub>1</sub> is ethyl, R<sub>2</sub> is methyl, and R<sub>3</sub> and R<sub>4</sub> are H.

25 12. A method according to claim 7, wherein R<sub>1</sub> is (CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, R<sub>2</sub> is methyl, and R<sub>3</sub> and R<sub>4</sub> are H.

13. A method according to claim 1, wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and/or R<sub>4</sub> is a peptide or peptidomimetic moiety.

1/13





FIG. 1

2/13



MOLECULAR MINIKRY OF SUBSTRATE MOTIF BY MIMETICA

FIG. 2b


 $\beta$ -TURN OF SUBSTRATE MOTIF

FIG. 2a

3/13







FIG. 2c

4/13

**FIG. 3a****FIG. 3b**

5/13



**FIG. 4a**

6/13



*FIG. 4c*



*FIG. 4b*

7/13




FIG. 5c




FIG. 5b




FIG. 5a

8/13




FIG. 5f




FIG. 5e






FIG. 5d

9/13

**FIG. 6a****FIG. 6b**

10/13






FIG. 7

11/13

FIG. 8



12/13



**FIG. 9**

13/13



FIG. 10a




FIG. 10b

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/26646

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 43/40

US CL : 514/348

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/348,372,350,185:435/6:424/423.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Please See Extra Sheet.

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A         | US 5,518,729 A (MARGOLIN) 21 May 1996, abstract.                                   | 1-15                  |
| A         | US 5,620,995 A (WEIDMANN et al.) 15 April 1997 abstract.                           | 1-15                  |
| A         | US 4,908,371 A (MOEKER et al) 13 March 1990, abstract & claims.                    | 1-15                  |
| A         | US 5,512,586 A (BICKEL et al) 30 April 1996, column 13, claims 1-2 & abstract.     | 1-15                  |

 Further documents are listed in the continuation of Box C. See patent family annex.

|   |     |  |
|---|-----|--|
| • Special categories of cited documents:  | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| • "A" document defining the general state of the art which is not considered to be of particular relevance  | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| • "B" earlier document published on or after the international filing date  | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| • "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Z" | document member of the same patent family  |
| • "O" document referring to an oral disclosure, use, exhibition or other means  |     |  |
| • "P" document published prior to the international filing date but later than the priority date claimed  |     |  |

Date of the actual completion of the international search

08 FEBRUARY 1999

Date of mailing of the international search report

19 MAR 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

VICKIE KIM

Telephone No. 703-308-1235

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US98/26646

**B. FIELDS SEARCHED**

Documentation other than minimum documentation that are included in the fields searched:

McCaffewy et al., " Specific Inhibition of cIF-5A and collagen Hydroxylation by single agent:...." Journal of clinical Investigation, 95:446-455(1995).